Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to & lt; 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)

ConclusionsIn this open-label study, crisaborole was well tolerated and effective in infants (3 to < 24 months) with mild-to-moderate AD with systemic exposures similar to patients aged ≥ 2 years.Clinical Trial RegistrationNCT03356977.

http://link.springer.com/10.1007/s40257-020-00510-6

Source: American Journal of Clinical Dermatology - March 23, 2020 Category: Dermatology Source Type: research